Atom Investors LP Poseida Therapeutics, Inc. Transaction History

Atom Investors LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.0 - $3.46 $447,812 - $774,714	-223,906 Reduced 36.13%	395,768 $1.16 Million
Q1 2024 May 15, 2024	BUY	$2.76 - $4.13 $728,800 - $1.09 Million	264,058 Added 74.25%	619,674 $1.98 Million
Q4 2023 Feb 14, 2024	BUY	$1.83 - $3.51 $364,989 - $700,062	199,448 Added 127.71%	355,616 $1.19 Million
Q3 2023 Nov 14, 2023	BUY	$1.62 - $2.79 $172,943 - $297,846	106,755 Added 216.05%	156,168 $371,000
Q2 2023 Aug 14, 2023	BUY	$1.66 - $3.4 $30,299 - $62,060	18,253 Added 58.58%	49,413 $86,000
Q1 2023 May 15, 2023	SELL	$3.08 - $8.73 $6,206 - $17,590	-2,015 Reduced 6.07%	31,160 $95,000
Q4 2022 Feb 14, 2023	SELL	$3.33 - $6.38 $396,086 - $758,869	-118,945 Reduced 78.19%	33,175 $175,000
Q3 2022 Nov 08, 2022	BUY	$2.43 - $4.51 $233,991 - $434,281	96,293 Added 172.48%	152,120 $537,000
Q2 2022 Aug 15, 2022	BUY	$1.87 - $5.0 $28,063 - $75,035	15,007 Added 36.76%	55,827 $144,000
Q1 2022 May 16, 2022	BUY	$3.22 - $7.04 $51,156 - $111,844	15,887 Added 63.72%	40,820 $183,000
Q4 2021 Feb 14, 2022	BUY	$6.23 - $7.6 $155,332 - $189,490	24,933 New	24,933 $170,000

38.5M

377K

22.2K

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $237M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

Get notified when there are updates to the investment portfolio of Atom Investors LP, based on Form 13F filings with the SEC.

Stay updated on Atom Investors LP with notifications on news.